Relay Therapeutics
RLAY
137 hedge funds and large institutions have $2.96B invested in Relay Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 65 increasing their positions, 26 reducing their positions, and 6 closing their positions.
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
150% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 26
19% more funds holding
Funds holding: 115 → 137 (+22)
18% more funds holding in top 10
Funds holding in top 10: 11 → 13 (+2)
0% more call options, than puts
Call options by funds: $17K | Put options by funds: $17K
2.34% less ownership
Funds ownership: 97.46% → 95.12% (-2.3%)
19% less capital invested
Capital invested by funds: $3.64B → $2.96B (-$685M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$62.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.3M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$34M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$439M |
| 2 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$117M |
| 3 |
CC
Casdin Capital
New York
|
-$18.8M |
| 4 |
PA
Perceptive Advisors
New York
|
-$13.5M |
| 5 |
AI
Alphabet Inc
Mountain View,
California
|
-$10.1M |
RLAY Hedge Fund Activity: Q1 2021 in Review
137 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q1 2021, worth a combined $2.96B — down 19% from $3.64B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RLAY positions and 6 closed out — a net gain of 22 holders — while 65 added to existing stakes and 26 trimmed.
The largest buyer was Vanguard Group, adding an estimated $101M. The largest seller was TRV GP III, exiting entirely with an estimated $439M sold.
- 137 institutional investors held Relay Therapeutics (RLAY) as of Q1 2021, up from 115 in Q4 2020.
- Funds reported $2.96B of Relay Therapeutics stock for Q1 2021, down 19% quarter-over-quarter.
- 28 funds opened new Relay Therapeutics positions in Q1 2021 and 6 closed out, a net change of +22 holders.
- The largest Relay Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $101M added.
- The largest Relay Therapeutics seller in Q1 2021 was TRV GP III, an estimated $439M sold.
Based on aggregated 13F filings for Q1 2021.